PROTECT Study (Summerfield 2012): Pimobendan in Preclinical DCM in Doberman Pinschers

Bottom line

• The PROTECT study (Summerfield et al. 2012, J Vet Intern Med) is the pivotal RCT demonstrating pimobendan's benefit in preclinical dilated cardiomyopathy (DCM) in Doberman Pinschers: 76 Dobermans at 10 centers in the UK and North America were randomized to pimobendan or placebo.¹
• Pimobendan significantly prolonged median time to the composite primary endpoint (onset of CHF or sudden death): 718 days (IQR 441–1152) in the pimobendan group versus 441 days (IQR 151–641) in placebo (log-rank P = .0088).¹
• Median survival time was also significantly longer in the pimobendan group (623 days, IQR 491–1531) versus placebo (466 days, IQR 236–710) (log-rank P = .034).¹
• The PROTECT study establishes a parallel preclinical treatment rationale to the EPIC trial in MMVD, and the 2019 ACVIM consensus guidelines incorporate pimobendan for echocardiographically confirmed preclinical DCM in appropriate breeds.²
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

A specific patient with preclinical DCM?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Study design and population

PROTECT was a randomized, blinded, placebo-controlled, parallel-group, multicenter study in 76 client-owned Doberman Pinschers with echocardiographically confirmed preclinical DCM, recruited at 10 centers in the UK and North America.¹ Dogs were allocated 1:1 to pimobendan (Vetmedin capsules) or visually identical placebo. The composite primary endpoint was prospectively defined as either onset of CHF or sudden death; time to death from all causes was a secondary endpoint.¹

The Doberman Pinscher is a breed with high prevalence of DCM and a well-characterized preclinical echocardiographic phase — making it an appropriate model for studying preclinical intervention. Preclinical DCM in this trial was defined by echocardiographic criteria consistent with the occult (hidden) phase before clinical signs develop.

Primary and secondary results

The proportion of dogs reaching the primary endpoint was not significantly different between groups overall (P = .1), reflecting the smaller sample size, but time-to-event analysis showed a significant benefit: median time to the primary endpoint was 718 days (IQR 441–1152) in the pimobendan group versus 441 days (IQR 151–641) in placebo (log-rank P = .0088).¹ Median survival time was also significantly extended: 623 days (IQR 491–1531) for pimobendan versus 466 days (IQR 236–710) for placebo (log-rank P = .034).¹ The authors concluded: "The administration of pimobendan to Dobermans with preclinical DCM prolongs the time to the onset of clinical signs and extends survival. Treatment of dogs in the preclinical phase of this common cardiovascular disorder with pimobendan can lead to improved outcome."¹

Parallel to MMVD preclinical evidence

PROTECT mirrors the EPIC study in its central design element: both tested pimobendan versus placebo in an asymptomatic echocardiographic phase of progressive cardiac disease, and both showed approximately 9–15 months of additional preclinical time. Taken together with EPIC (MMVD, Stage B2) and QUEST (CHF from MMVD), PROTECT completes a compelling evidence chain demonstrating pimobendan's utility across both major forms of canine cardiac disease — valvular and myocardial — and across disease stages from preclinical to symptomatic CHF. The ACVIM 2019 consensus guidelines note these study data when addressing management of DCM alongside MMVD.²

How this fits clinical practice

For Doberman Pinschers with echocardiographically confirmed preclinical DCM, PROTECT provides clear RCT-level support for pimobendan initiation before clinical signs develop. Echocardiographic screening of Dobermans — recommended by breed health organizations and supported by the cardiac disease literature — is therefore the diagnostic gateway to identifying candidates for preclinical intervention. For breeds other than Dobermans with DCM, direct trial evidence from PROTECT does not automatically extrapolate, though the ACVIM guidelines provide broader guidance. Do not infer specific doses from this summary; confirm the exact regimen, monitoring protocol, and contraindications against current product labeling and a veterinary formulary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Summerfield NJ, Boswood A, O'Grady MR, et al. 2012. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT study). J Vet Intern Med 26(6):1337-1349. https://europepmc.org/article/MED/23078651
2. Keene BW, Atkins CE, Bonagura JD, et al. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33(3):1127-1140. https://europepmc.org/article/MED/30974015 [via]

Changelog

• 2026-06-22: First published.